MRA(Tocilizumab)
Phase 3Monoclonal antibody
RocheMRA(Tocilizumab) is one of 48 small molecule programs targeting Systemic Juvenile Idiopathic Arthritis. It is currently in Phase 3.
3
Indications
13
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1MRA(Tocilizumab)
RochePhase 3
Rituxan
RochePreclinical
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rheumatoid Arthritis9 trials
Show 6 more trials
Polyarticular Juvenile Idiopathic Arthritis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRA(Tocilizumab). EMBL-EBI & Wellcome Sanger Institute.
- [4]